^
    Back
    Association details:
    Biomarker:IDO1 overexpression
    Cancer:Non Small Cell Lung Cancer
    Drug Class:PD-L1 inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Cancer Res
    Title:

    Upregulation of Indoleamine 2,3-dioxygenase 1 in tumor cells and tertiary lymphoid structures is a hallmark of inflamed non-small cell lung cancer

    Published date:
    09/26/2023
    Excerpt:
    The increased expression of the tryptophan-catabolizing enzyme indoleamine 2,3-dioxygenase 1 (IDO1) was significantly associated with improved objective response, progression-free survival and overall survival in patients treated with PDL1 inhibitor but not in those treated with chemotherapy.
    DOI:
    https://doi.org/10.1158/1078-0432.CCR-23-1928